Skip to main content
Premium Trial:

Request an Annual Quote

GnuBio Raises $10M in Private Financing

NEW YORK (GenomeWeb News) – GnuBio today said that it has completed a $10 million Series B round of financing with private investors.

The Cambridge, Mass.-based firm didn't disclose the names of the investors but said that the round included investors from its Series A round. GnuBio completed that $8 million Series A round a year ago, and it also declined to disclose the names of the investors at that time.

In a statement today, the firm said that it would use the funds to commercialize its desktop DNA sequencing platform and hire additional staff in product development, informatics, and software engineering. It also intends to hire sales and marketing staff within the next year as it prepares to launch its first product for targeted DNA sequencing.

The firm's platform integrates a workflow in a single desktop system and targets applications in ingectious diseases, oncology, and cardiovascular disease, among others. GnuBio shipped an early-access instrument to the Montreal Heart Institute last year and intends to begin delivering commercial systems next year.

"Our funding, along with the recent government grant funding of $4.5 million, will help us translate our platform microfluidic technology into products for targeted and whole genome sequencing," GnuBio President, CEO, and Co-founder John Boyce said.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.